{
  "openalex_id": "W2501091063",
  "doi": "https://doi.org/10.1158/1538-7445.am2016-1464",
  "title": "Abstract 1464: The tumor immune microenvironment is similar in anal squamous cell carcinomas (SCCs) from HIV-infected and uninfected patients",
  "abstract": "Abstract Tumors may evade immune attack by constitutive (oncogene-driven) and/or adaptive (IFN-g inducible) expression of PD-L1. PD-1/PD-L1 blockade can mediate tumor regression in immunocompetent patients. In HIV-infected patients, developing tumors may face little immune selection pressure and therefore may not evolve to evade immune attack. Expression of PD-L1 has not been systematically assessed in cancers from HIV-infected people. In the current study, immunohistochemistry for PD-L1, and CD3 and CD68 (immune cells, ICs) was performed on biopsies from 46 anal SCCs, including 27 from HIV-infected and 19 from uninfected patients. The proportion of cases with tumor cell PD-L1 expression was similar in patients with and without HIV (52% vs. 47%, respectively, p = 0.76), as was the presence of moderate/severely dense ICs (33% vs. 37%, p = 0.81) (Table). Among HIV-infected patients, 19% of anal SCC tumors (5/27) both expressed PD-L1 and had moderate/severe IC infiltration. Tumors from HIV-infected and uninfected patients had similar densities of CD68+ macrophages (mean 517 vs. 404 cells/mm2, p = 0.33) and CD3+ T- lymphocytes (mean 501 vs. 428 cells/mm2, p = 0.57). A component of adaptive PD-L1 expression (juxtaposed to tumor infiltrating ICs) was also observed in both groups (56% vs. 47%, p = 0.58), consistent with comparable T-cell functionality. Further studies will explore the expression of other immune checkpoint proteins and lymphocyte subsets. Despite expectations that cancers from HIV-infected patients would show reduced inflammation, our preliminary findings demonstrate an immune-reactive microenvironment in both HIV+ and HIV- anal SCCs and suggest that anti-PD-1/PD-L1 therapies should be evaluated in anal SCC patients. Tumor infiltrating ICTotalHIV- a (n = 19)HIV+ a (n = 27)P-value cNone-mildTotal3012 (40%)18 (60%)0.66PD-L1(+) b145 (36%)9 (64%)PD-L1(-)167 (44%)9 (56%)Moderate-severeTotal167 (44%)9 (56%)0.95PD-L1(+) b94 (44%)5 (56%)PD-L1(-)73 (43%)4 (57%)a Anal SCC tumors in HIV-infected patients include 19 tumors identified through the AIDS-Cancer Specimen Resource and 8 tumors identified at Johns Hopkins Hospital. Anal SCC tumors in HIV-uninfected patients include 1 tumor identified through the AIDS-Cancer Specimen Resource and 18 tumors identified at Johns Hopkins Hospital.b Defined as â‰¥5% of tumor cells expressing cell surface PD-L1 by immunohistochemistry with the 5H1 monoclonal antibody.c P-values are for the comparison of PD-L1 expression between HIV+ and HIV- anal SCCs within strata of tumor infiltrating ICIC = immune cells Citation Format: Elizabeth L. Yanik, Suzanne L. Topalian, Genevieve Kaunitz, Jessica Esandrio, Tricia Cottrell, Janis M. Taube. The tumor immune microenvironment is similar in anal squamous cell carcinomas (SCCs) from HIV-infected and uninfected patients. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1464.",
  "authors": [
    {
      "display_name": "Elizabeth L. Yanik",
      "id": "A5068573463",
      "orcid": "https://orcid.org/0000-0002-5835-0201",
      "institutions": [
        {
          "id": "I4210140884",
          "display_name": "National Cancer Institute",
          "country_code": "US",
          "type": "government"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Elizabeth L. Yanik"
    },
    {
      "display_name": "Suzanne L. Topalian",
      "id": "A5052980036",
      "orcid": "https://orcid.org/0000-0002-0821-8587",
      "institutions": [
        {
          "id": "I4210106595",
          "display_name": "Sidney Kimmel Cancer Center",
          "country_code": "US",
          "type": "healthcare"
        },
        {
          "id": "I145311948",
          "display_name": "Johns Hopkins University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Suzanne L. Topalian"
    },
    {
      "display_name": "Genevieve J. Kaunitz",
      "id": "A5050595848",
      "orcid": "https://orcid.org/0000-0001-9619-0109",
      "institutions": [
        {
          "id": "I4210106595",
          "display_name": "Sidney Kimmel Cancer Center",
          "country_code": "US",
          "type": "healthcare"
        },
        {
          "id": "I145311948",
          "display_name": "Johns Hopkins University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Genevieve Kaunitz"
    },
    {
      "display_name": "Jessica Esandrio",
      "id": "A5048978530",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210106595",
          "display_name": "Sidney Kimmel Cancer Center",
          "country_code": "US",
          "type": "healthcare"
        },
        {
          "id": "I145311948",
          "display_name": "Johns Hopkins University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Jessica Esandrio"
    },
    {
      "display_name": "Tricia R. Cottrell",
      "id": "A5071088476",
      "orcid": "https://orcid.org/0000-0003-2952-1830",
      "institutions": [
        {
          "id": "I4210106595",
          "display_name": "Sidney Kimmel Cancer Center",
          "country_code": "US",
          "type": "healthcare"
        },
        {
          "id": "I145311948",
          "display_name": "Johns Hopkins University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Tricia Cottrell"
    },
    {
      "display_name": "Janis M. Taube",
      "id": "A5035471137",
      "orcid": "https://orcid.org/0000-0002-8273-4395",
      "institutions": [
        {
          "id": "I4210140884",
          "display_name": "National Cancer Institute",
          "country_code": "US",
          "type": "government"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Janis M. Taube"
    }
  ],
  "publication_year": 2016,
  "publication_date": "2016-07-15",
  "type": "article",
  "cited_by_count": 1,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S168522863",
    "display_name": "Cancer Research",
    "issn_l": "0008-5472",
    "issn": [
      "0008-5472",
      "1538-7445"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310320273"
  },
  "volume": "76",
  "issue": "14_Supplement",
  "first_page": "1464",
  "last_page": "1464",
  "open_access": {
    "is_oa": false,
    "oa_status": "closed",
    "oa_url": null,
    "any_repository_has_fulltext": false
  },
  "concepts": [
    {
      "id": "C8891405",
      "display_name": "Immune system",
      "level": 2,
      "score": 0.7035548
    },
    {
      "id": "C2776460901",
      "display_name": "CD68",
      "level": 3,
      "score": 0.5968965
    },
    {
      "id": "C2778326572",
      "display_name": "Tumor-infiltrating lymphocytes",
      "level": 4,
      "score": 0.58486104
    },
    {
      "id": "C2780851360",
      "display_name": "Immune checkpoint",
      "level": 4,
      "score": 0.5605115
    },
    {
      "id": "C159654299",
      "display_name": "Antibody",
      "level": 2,
      "score": 0.5035116
    },
    {
      "id": "C204232928",
      "display_name": "Immunohistochemistry",
      "level": 2,
      "score": 0.49908042
    },
    {
      "id": "C2779840525",
      "display_name": "Anal cancer",
      "level": 3,
      "score": 0.48146024
    },
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.4385081
    },
    {
      "id": "C114684123",
      "display_name": "CD3",
      "level": 4,
      "score": 0.43317413
    },
    {
      "id": "C121608353",
      "display_name": "Cancer",
      "level": 2,
      "score": 0.4313587
    },
    {
      "id": "C502942594",
      "display_name": "Cancer research",
      "level": 1,
      "score": 0.4132059
    },
    {
      "id": "C203014093",
      "display_name": "Immunology",
      "level": 1,
      "score": 0.39309126
    },
    {
      "id": "C2777701055",
      "display_name": "Immunotherapy",
      "level": 3,
      "score": 0.316958
    },
    {
      "id": "C167672396",
      "display_name": "CD8",
      "level": 3,
      "score": 0.27680585
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.2397472
    }
  ],
  "topics": [
    {
      "id": "T10158",
      "display_name": "Cancer Immunotherapy and Biomarkers",
      "score": 0.9986
    },
    {
      "id": "T13110",
      "display_name": "Colorectal and Anal Carcinomas",
      "score": 0.9968
    },
    {
      "id": "T10458",
      "display_name": "Bladder and Urothelial Cancer Treatments",
      "score": 0.9953
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1158/1538-7445.am2016-1464",
  "pdf_url": null,
  "retrieved_date": "2025-07-30T14:46:17.118339",
  "source_database": "OpenAlex"
}